Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | F2R | P25116 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3304544 | 0.85 | BRD4 (0.40) | BRD4SMN1; SMN2OPRM1OPRD1OPRK1 | |
| SCHEMBL13328493 | 0.85 | BRD4 (0.40) | BRD4SMN1; SMN2OPRM1OPRD1OPRK1 | |
| SCHEMBL7923194 | 0.84 | ABHD6 (0.34) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30801469 | 0.84 | BRD4 (0.51) | BRD4SMN1; SMN2OPRM1OPRD1OPRK1 | |
| SCHEMBL3306445 | 0.84 | BRD4 (0.51) | BRD4SMN1; SMN2OPRM1OPRD1OPRK1 | |
| SCHEMBL23856939 | 0.83 | BRD4 (0.43) | BRD4SMN1; SMN2OPRM1OPRD1OPRK1 | |
| SCHEMBL30253303 | 0.83 | BRD4 (0.43) | BRD4SMN1; SMN2OPRM1OPRD1OPRK1 | |
| SCHEMBL12203927 | 0.78 | KMT2A (0.36) | BRD4SMN1; SMN2OPRM1OPRD1OPRK1 | |
| SCHEMBL3304678 | 0.77 | OPRM1 (0.37) | BRD4SMN1; SMN2OPRM1OPRD1OPRK1 | |
| SCHEMBL3308197 | 0.77 | OPRM1 (0.40) | BRD4SMN1; SMN2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130225582-A1 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8476274-B2 | Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476274-B2 | Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP (US) | 2013-02-21 | — | — | US | disclosed |
| US-8324213-B2 | Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324213-B2 | Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110251207-A1 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251207-A1 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| WO-2010042473-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2010-04-15 | — | — | WO | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | BRD4 393/4885SMN1; SMN2 4779/4885OPRM1 450/4885 |
| US-20130225582-A1 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRA2A | BRD4 648/4885SMN1; SMN2 3466/4885OPRM1 160/4885 |
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRA2A | BRD4 784/4885SMN1; SMN2 2784/4885OPRM1 118/4885 |
| US-20110251207-A1 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRB3 | BRD4 473/4885SMN1; SMN2 3615/4885OPRM1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.